Here are three things to know:
1. CybroCell now comprises 36 U.S. and foreign issued patents with 40 pending.
2. The new patent involves differentiating human dermal fibroblast into chondrocyte-like cells by exposing them to a specific environment of growth factors, hypoxia, hydrostatic pressure and shear stress.
3. CybroCell is an off-the-shelf allogenic human dermal fibroblast product designed to treat degenerative disc disease.
More articles on biologics:
DiscGenics’ cell therapy passes safety review of first-in-human trial: 5 things to know
3 things to know about JRF Ortho
StemCyte gets FDA green light to continue studying spinal cord injury treatment stem cells: 5 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
